JAZZ Financials

Income Statement
MetricQ3 2026Q2 2026Q1 2026Q4 2025Q3 2025
Revenue
1.2B
+2.9%
1.2B
+13.0%
1.1B
-10.8%
1.2B
+6.4%
1.1B
Cost of Revenue
110.6M
-5.0%
116.4M
-13.2%
134.1M
-12.7%
153.5M
+19.1%
128.9M
Gross Profit
1.1B
+3.7%
1.1B
+16.8%
934.8M
-10.5%
1.0B
+4.7%
997.2M
Operating Expenses
1.5B
+83.2%
843.7M
+17.0%
721.0M
-8.7%
789.9M
-15.9%
939.7M
R&D
211.9M
+2.1%
207.5M
+5.9%
196.0M
-8.4%
213.9M
+7.9%
198.2M
SG&A
407.9M
+4.8%
389.2M
+10.3%
352.7M
-13.2%
406.2M
-23.4%
530.6M
Operating Income
-413400000
-266.6%
248.2M
+16.1%
213.8M
-16.0%
254.5M
+342.7%
57.5M
EBITDA
519.7M
+3.1%
504.3M
+27.6%
395.2M
-8.9%
433.7M
+55.8%
278.3M
Net Income
-483400000
-350.7%
192.8M
-34.2%
293.1M
+44.1%
203.5M
-19.1%
251.4M
EPS (Basic)
$-7.48
-345.2%
$3.05
-35.5%
$4.73
+42.0%
$3.33
-19.6%
$4.14
EPS (Diluted)
$-7.48
-369.1%
$2.78
-37.2%
$4.43
+31.1%
$3.38
-17.2%
$4.08
Shares (Diluted)
64.7M
-6.8%
69.4M
+5.0%
66.1M
+9.9%
60.1M
-2.4%
61.6M
Jazz Pharmaceuticals (JAZZ) — Financials